natgillin/translations-raw huggingface dataset:
DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens-Johnson syndrome has been rarely (< 0.1%) reported, and during post-marketing experience toxic epidermal necrolysis and acute generalised exanthematous pustulosis have been reported.
DRESS (osip izazvan lijekom s eozinofilijom i sistemskim simptomima) i Stevens-Johnsonov sindrom bili su rijetko (< 0,1%) prijavljivani, a tijekom postmarketinškog iskustva prijavljene su toksička epidermalna nekroliza i akutna generalizirana egzantematozna pustuloza.
Cold form PVC/Al/OPA-Al blister pack This medicinal product does not require any special storage conditions.
Hladno oblikovano PVC/Al/OPA-Al blister pakiranje Lijek ne zahtijeva posebne uvjete čuvanja.
α1-ADRENORECEPTOR ANTAGONIST Alfuzosin
α1-ANTAGONIST ADRENORECEPTORA Alfuzozin
Very common side effects (may affect more than 1 in 10 people) - diarrhoea.
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) - proljev.
Hence, the use of creatinine clearance as an estimate of renal elimination capacity may be misleading.
Stoga, korištenje klirensa kreatinina za procjenu kapaciteta eliminacije bubrezima može dovesti do krivog zaključka.
Nervous system disorders Very common headache
Poremećaji živčanog sustava vrlo često glavobolja
Tenofovir alafenamide ↔ Tenofovir ↑
Tenofoviralafenamid ↔ Tenofovir ↑
Midazolam (parenteral) Zoldipem
Midazolam (parenteralni) Zoldipem
Infections and infestations Uncommon herpes simplex
Infekcije i infestacije manje često herpes simpleks
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
Ako primjetite bilo koji simptom infekcije ili drugi simptom poput mišićne slabosti, slabosti koja počinje u šakama i stopalima te se širi gore prema trupu tijela, lupanja srca, tremora ili hiperaktivnosti, molimo Vas odmah obavijestite liječnika i zatražite potrebno liječenje.
Co-administration with CYP3Ametabolised corticosteroids is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid effects.
Istodobna primjena s kortikosteroidima koje metabolizira CYP3A ne preporučuje se osim ako potencijalna korist za pacijenta nadilazi rizik, a u tom slučaju pacijente treba nadzirati radi pojave sistemskih učinaka kortikosteroida.
Your doctor will advise you how to deal with your symptoms or whether darunavir must be stopped.
Liječnik će Vam savjetovati što učiniti vezano uz pojavu simptoma i morate li prestati s uzimanjem darunavira.
GS-US-216-130 Week 48
GS-US-216-130 48. tjedan
Darunavir works by reducing the amount of HIV in your body.
Darunavir djeluje tako da smanjuje količinu virusa HIV-a u Vašem tijelu.
- Swallow the tablets with a drink such as water or milk.
- Progutajte tablete s pićem poput vode ili mlijeka.
● For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.
Za liječenje HIV-1 infekcije u odraslih bolesnika prethodno liječenih antiretrovirusnom terapijom (ART), uključujući bolesnike koji su prethodno bili liječeni u znatnoj mjeri.
● For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least
Za liječenje HIV-1 infekcije u pedijatrijskih bolesnika u dobi od 3 godine i težine najmanje 15
- Unlike ritonavir, cobicistat does not have inducing effects on enzymes or transport proteins (see section 4.5).
- Za razliku od ritonavira, kobicistat nema inducirajuće učinke na enzime ili prijenosne proteine (vidjeti dio 4.5).
<PVC/PE/PVDC-Al blister pack only> Do not store above 25°C.
<samo za blister pakiranje PVC/PE/PVDC-Al> Ne čuvati na temperaturi iznad 25 °C.
SEDATIVES/HYPNOTICS Buspirone
SEDATIVI/HIPNOTICI Buspiron
This cannot be administered with these 75 milligram tablets.
To se ne može primijeniti s ovim tabletama od 75 miligrama.
Therefore, clinical monitoring is recommended, as maintenance therapy may need to be adjusted in some patients.
Stoga se preporučuje kliničko praćenje, s obzirom da je kod nekih bolesnika potrebno prilagoditi terapiju održavanja.
These medicines are used to treat allergies, asthma, inflammatory bowel diseases, inflammatory conditions of the eyes, joints and muscles and other inflammatory conditions.
Ti se lijekovi upotrebljavaju za liječenje alergija, astme, upalne bolesti crijeva, upalnog stanja očiju, zglobova i mišića te ostalih upalnih stanja.
Do not use this medicine after the expiry date which is stated on the carton, blister and on the bottle after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, blisteru i boci iza „Rok valjanosti“ ili „EXP“.
One darunavir dose is
Jedna doza darunavira je
These are: - muscle pain, tenderness or weakness.
To su: - bol u mišićima, osjetljivost na dodir ili slabost.
In rodents the target organs identified were the haematopoietic system, the blood coagulation system, liver and thyroid.
Kod glodavaca, ciljni organi su bili hematopoetski sustav, sustav koagulacije krvi, jetra i štitnjača.
The dose of cobicistat to be used with darunavir in children less than 18 years of age has not been established.
Doza kobicistata koja se treba uzeti uz darunavir u djece dobi mlađe od 18 godina nije ustanovljena.
Furthermore, AUC of the sum of active moieties of rifabutin (parent drug + 25-Odesacetyl metabolite) was increased 1.6-fold, while Cmax remained comparable.
Osim toga, AUC zbroja aktivnih komponenti rifabutina (izvorni lijek + 25-O-desacetil metabolit) povišen je 1,6 puta, dok je Cmax ostala usporediva.
Darunavir was not mutagenic or genotoxic in a battery of in vitro and in vivo assays including bacterial reverse mutation (Ames), chromosomal aberration in human lymphocytes and in vivo micronucleus test in mice.
Darunavir nije bio mutagen ili genotoksičan u setu in vitro i in vivo testova uključujući reverznu bakterijsku mutaciju (Ames), kromosomsku aberaciju u ljudskim limfocitima te in vivo mikroneukleusni test kod miševa.
It is recommended that HIV infected women must not breast-feed their infants because of both the possibility of your baby becoming infected with HIV through your breast milk and because of the unknown effects of the medicine on your baby.
Preporuča se da žene zaražene HIV-om ne smiju dojiti djecu zbog mogućnosti prijenosa HIV-a na dijete putem majčina mlijeka te zbog nepoznatih učinaka koje lijek može imati na Vaše dijete.
Dose (twice daily with food)
Doza (dva puta na dan s hranom)
Cmax, ng/ml AUC12h, ng.h/ml Cmin, ng/ml a n=11 for AUC12h
Cmax, ng/ml AUC12h, ng.h/ml Cmin, ng/ml a n=11 za AUC12h
Darunavir might increase sugar levels in the blood.
Darunavir može povisiti razine šećera u krvi.
Darunavir might increase the risk of bleeding.
Darunavir može povećati rizik krvarenja.
Pregnant or breast-feeding mothers must not take darunavir with ritonavir unless specifically directed by the doctor.
Trudnice ili dojilje ne smiju uzimati darunavir s ritonavirom osim ako to liječnik posebno ne odredi.
Patients with severe (Child-Pugh Class C) hepatic impairment.
Bolesnici s teškim oštećenjem jetre (Child-Pugh stadij C).
The doctor will determine if once daily dosing or twice daily dosing is appropriate for the child.
Liječnik će odrediti je li za dijete prikladno doziranje od jedanput na dan ili dva puta na dan.
TITAN Week 48
TITAN 48. tjedan
Instructions for children - The child must take darunavir always together with ritonavir.
Upute za djecu - Dijete uvijek mora uzimati darunavir zajedno s ritonavirom.
Mylan Hungary Kft H-2900 Komárom, Mylan utca 1 Hungary
Mylan Hungary Kft H-2900 Komárom, Mylan utca 1 Mađarska
Darunavir cannot work properly without food.
Darunavir ne može pravilno djelovati bez hrane.
In the dog, no major toxicity findings or target organs were identified up to exposures equivalent to clinical exposure at the recommended dose.
Kod pasa nije nađena veća toksičnost ciljnih organa pri izloženostima jednakim kliničkoj izloženosti pri preporučenoj dozi.
Once daily dosing Weight
Doziranje jedanput na dan Težina
Domperidone
Domperidon
In a pre- and postnatal development assessment in rats, darunavir with and without ritonavir, caused a transient reduction in body weight gain of the offspring pre-weaning and there was a slight delay in the opening of eyes and ears.
U procjeni prenatalnog i postnatalnog razvoja kod štakora, darunavir sa ili bez ritonavira, uzrokovao je prolazno smanjenje dobivanja tjelesne težine kod mladunčadi do prestanka laktacije, a također je došlo do nešto odgođenog otvaranja očiju i ušiju.
These patients received darunavir/ritonavir twice daily in combination with other antiretroviral agents (see section 4.2 for dosage recommendations per body weight).
Ovi bolesnici primali su darunavir/ritonavir dva puta na dan u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 4.2 za preporuke o doziranju prema tjelesnoj težini).
No dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, darunavir should be used with caution in these patients.
Ne preporučuje se prilagodba doze u bolesnika s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem jetre, međutim darunavir se u tih bolesnika mora primjenjivati s oprezom.
Darunavir/ritonavir should not be used in children with a body weight of less than 15 kg as the dose for this population has not been established in a sufficient number of patients (see section 5.1).
Darunavir/ritonavir se ne smiju primjenjivati u djece s tjelesnom težinom manjom od 15 kg, jer doza za ovu populaciju nije ustanovljena na dovoljnom broju bolesnika (vidjeti dio 5.1).
The dose of cobicistat to be used with Darunavir has not been established in this patient population.
Doza kobicistata koja se uzima s lijekom Darunavir nije bila ustanovljena u ovoj populaciji bolesnika.
In the study, patients who were at risk of discontinuing therapy due to intolerance of ritonavir oral solution (e.g. taste aversion) were allowed to switch to the capsule formulation.
U ispitivanju je bilo dozvoljeno bolesnicima koji su bili pod rizikom od prekida terapije zbog nepodnošenja ritonavir oralne otopine (npr. nepodnošenje okusa) prijeći na oblik u kapsulama.
The exposure-adjusted rates of rash (all causality) were 10.9, 4.2, and 3.8 per 100 patient-years (PYR), respectively; and for drug-related rash were 2.4, 1.1, and 2.3 per 100 PYR, respectively.
Stope osipa prilagođene izloženosti (svih uzroka) bile su 10,9; 4,2 odnosno 3,8 na 100 bolesnik-godina, a za osip povezan s lijekom bile su 2,4; 1,1 odnosno 2,3 na 100 bolesnik-godina.
Due to uncertainties regarding the rate of development of the human blood brain barrier and liver enzymes, darunavir with low dose ritonavir should not be used in paediatric patients below 3 years of age.
S obzirom na nesigurnost vezanu uz poznavanje brzine razvoja ljudske krvno-moždane barijere i jetrenih enzima, darunavir s niskom dozom ritonavira ne smije se primjenjivati pedijatrijskim bolesnicima mlađima od 3 godine starosti.
The safety and efficacy of darunavir have not been established in patients with severe underlying liver disorders and darunavir is therefore contraindicated in patients with severe hepatic impairment.
Sigurnost i djelotvornost darunavira nije ustanovljena kod bolesnika s teškim podležećim poremećajima jetre, stoga je darunavir kontraindiciran kod bolesnika s teškim oštećenjem jetre.
- Atorvastatin, pravastatin, rosuvastatin (to lower cholesterol levels).
- atorvastatin, pravastatin, rosuvastatin (za snižavanje razina kolesterola).
Total number of virologic failuresa, n (%) Rebounders
Ukupni broj viroloških neuspjeha a, n (%)
C-darunavir trial in healthy volunteers showed that a majority of the radioactivity in plasma after a single 400/100 mg darunavir with ritonavir dose was due to the parent active substance.
C-darunavir na zdravim dobrovoljcima pokazalo je da većinu radioaktivnosti u plazmi nakon jednostruke doze od 400/100 mg darunavira s ritonavirom treba pripisati osnovnoj djelatnoj tvari.
Darunavir Mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:
Tablete Darunavir Mylan od 400 mg i 800 mg mogu se primjenjivati da bi se osigurali prikladni režimi doziranja za liječenje HIV-1 infekcije u odraslih i pedijatrijskih bolesnika od 3 godine starosti i tjelesne težine barem 40 kg koji:
What Darunavir Mylan is and what it is used for What you need to know before you take Darunavir Mylan How to take Darunavir Mylan Possible side effects
Što je Darunavir Mylan i za što se koristi Što morate znati prije nego počnete uzimati lijek Darunavir Mylan Kako uzimati lijek Darunavir Mylan Moguće nuspojave
Exposure to darunavir was higher in HIV-1 infected patients than in healthy subjects.
Izloženost darunaviru bila je viša kod bolesnika inficiranih s HIV-1 nego kod zdravih ispitanika.
The table below shows the efficacy data of the 48 week analyses from the GS-US-216-130 trial:
Tablica ispod pokazuje podatke djelotvornosti iz analize nakon 48 tjedana iz ispitivanja GS-US-216-130:
In repeated-dose toxicology studies in mice, rats and dogs, there were only limited effects of treatment with darunavir.
U ispitivanjima toksičnosti ponovljenih doza kod miševa, štakora i pasa, postojali su samo ograničeni učinci na liječenje darunavirom.
Your child's doctor will determine the appropriate dosing regimen for your child. - The child must take darunavir with food.
Liječnik Vašeg djeteta će odrediti prikladni režim doziranja za Vaše dijete.
Instructions for adults - Take darunavir always together with ritonavir.
Upute za odrasle - Darunavir uvijek uzimajte zajedno s ritonavirom.
675 milligram
675 miligrama
After 2 years administration of darunavir at exposures at or below the human exposure, kidney changes were observed in mice (nephrosis) and rats (chronic progressive nephropathy).
Nakon 2 godine primjene darunavira pri izloženostima koja je jednaka ili ispod izloženosti kod ljudi, primijećene su promjene na bubrezima kod miševa (nefroza) i štakora (kronična progresivna nefropatija).
However, for unbound (i.e. active) darunavir, the pharmacokinetic parameters were less reduced during pregnancy compared to postpartum, due to an increase in the unbound fraction of darunavir during pregnancy compared to postpartum.
Ipak, farmakokinetički parametri darunavira koji se nije vezao (tj. aktivnog), bili su manje sniženi tijekom trudnoće u usporedbi s postpartalnim razdobljem, zbog povišenja nevezane frakcije darunavira tijekom trudnoće u odnosu na postpartalno razdoblje.
The use of 75 mg and 150 mg tablets to achieve the recommended dose is appropriate when there is a difficulty in swallowing the 300 mg or 600 mg tablets.
Primjena tableta od 75 mg i 150 mg za dostizanje preporučene doze primjerena je kada postoje teškoće pri gutanju tableta od 300 mg ili 600 mg.
Severe hepatic impairment could result in an increase of darunavir exposure and a worsening of its safety profile.
Teško oštećenje jetre može rezultirati povećanom izloženosti darunaviru i pogoršati njegov sigurnosni profil.
For the treatment of pulmonary arterial hypertension Sildenafil
Za liječenje plućne arterijske hipertenzije Sildenafil Tadalafil
Tenofovir disoproxil 245 mg once daily‡
Tenofovirdizoproksil 245 mg jedanput na dan‡
At the highest tested doses, the systemic exposures (based on AUC) to darunavir were between 0.4- and 0.7-fold (mice) and 0.7- and 1-fold (rats), relative to those observed in humans at the recommended therapeutic doses.
Pri najvišim ispitivanim dozama, sistemske izloženosti darunaviru (temeljene na AUC), bila je veća između 0,4 i 0,7 puta (kod miševa) te 0,7 i 1 puta (kod štakora), u odnosu na opaženu izloženost kod ljudi pri preporučenom terapijskim dozama.
- Apixaban, edoxaban, rivaroxaban, warfarin (to reduce clotting of the blood) as their therapeutic effect or side effects may be altered; your doctor may have to check your blood.
- apiksaban, edoksaban, rivaroksaban, varfarin (smanjuje zgrušavanje krvi), jer terapijski učinak ili nuspojave mogu biti izmijenjene; liječnik će Vam možda htjeti provjeriti krvnu sliku.
In most cases, darunavir can be combined with anti-HIV medicines belonging to another class [e.g.
U većini slučajeva darunavir se može kombinirati s lijekovima protiv HIV-a koji pripadaju drugoj skupini [npr.
The doctor will inform you on how much Darunavir Mylan tablets and how much ritonavir (capsules, tablets or solution) the child must take.
Liječnik će Vas informirati koliko Darunavir Mylan tableta i koliko ritonavira (kapsula, tableta ili otopine) dijete mora uzeti.
The risk of muscle damage might be increased.
Može biti povećan rizik od oštećenja mišićnog tkiva.
The absolute oral bioavailability of a single 600 mg dose of darunavir alone was approximately 37% and increased to approximately 82% in the presence of 100 mg twice daily ritonavir.
Apsolutna peroralna bioraspoloživost jednokratne doze od 600 mg samog darunavira bila je približno 37% i porasla na približno 82% u prisutnosti ritonavira od 100 mg dva puta na dan.
Following intravenous administration, the volume of distribution of darunavir alone was 88.1 ± 59.0 l (Mean ± SD) and increased to 131 ± 49.9 l (Mean ± SD) in the presence of 100 mg twice-daily ritonavir.
Nakon intravenske primjene, volumen distribucije samog darunavira bio je 88,1 ± 59,0 l (srednja vrijednost ± SD) i povećao se na 131 ± 49,91 (srednja vrijednost ± SD) u prisutnosti 100 mg ritonavira dva puta na dan.
For co-administration with strong CYP3A4 inhibitors, the same recommendations apply independent of whether darunavir is boosted with ritonavir or with cobicistat (see section above).
Za istodobnu primjenu sa snažnim CYP3A4 inhibitorima, odnose se iste preporuke, neovisno o tome je li darunavir pojačan s ritonavirom ili kobicistatom (vidjeti odjeljak iznad).
How to store Darunavir Mylan Contents of the pack and other information
Kako čuvati lijek Darunavir Mylan Sadržaj pakiranja i druge informacije
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy (CART).
Iako se smatra da je etiologija višeznačna (uključuje primjenu kortikosteroida, konzumaciju alkohola, tešku imunosupresiju, viši indeks tjelesne mase), slučajevi osteonekroze prijavljeni su naročito kod bolesnika s uznapredovalom HIV bolešću i/ili s dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji (KART).
There were no new clinically relevant safety findings compared with the known safety profile of darunavir/ritonavir in HIV-1 infected adults (see sections 4.2, 4.4 and 5.2).
Nisu zabilježeni novi klinički značajni sigurnosni podaci u usporedbi s poznatim sigurnosnim profilom darunavira/ritonavira u HIV-1 inficiranih odraslih bolesnika (vidjeti dijelove 4.2, 4.4 i 5.2).
Results from a mass balance study with
Rezultati ispitivanja masene ravnoteže s
HMG CO-A REDUCTASE INHIBITORS Lovastatin
INHIBITORI HMG-Co-A REDUKTAZA Lovastatin
Instructions for adults - Take two 400 milligram tablets at the same time, once a day, every day.
Upute za odrasle - Uzimite po dvije tablete od 400 miligrama u isto vrijeme, jedanput na dan, svaki dan.
Didanosine is to be administered on an empty stomach, thus it should be administered 1 hour before or 2 hours after darunavir/ritonavir given with food.
Didanozin treba primijeniti na prazan želudac, odnosno treba ga primijeniti 1 sat prije ili 2 sata nakon lijekova darunavir/ritonavir koji se uzimaju s hranom.
- Tell your doctor if you have diabetes.
- Upozorite liječnika ako imate šećernu bolest.
6/l (see section 4.2 and 4.4).
6/l (vidjeti dio 4.2 i 4.4).
The recommended dose of darunavir with low dose ritonavir should not exceed the recommended adult dose (600/100 mg twice daily or 800/100 mg once daily).
Preporučena doza darunavira uz nisku dozu ritonavira ne smije prelaziti preporučenu dozu za odrasle (600/100 mg dva puta na dan ili 800/100 mg jedanput na dan).
Fluticasone: in a clinical study where ritonavir 100 mg capsules twice daily were co-administered with 50 μg intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, fluticasone propionate plasma concentrations increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% CI 8289%).
Flutikazon: u kliničkom ispitivanju gdje su ritonavir 100 mg kapsule dva puta na dan istodobno primijenjene s 50 g intranazalnog flutikazon propionata (4 puta na dan) tijekom 7 dana kod zdravih ispitanika, značajno su porasle koncentracije flutikazon propionata u plazmi, dok su se razine intrinzičnog kortizola snizile približno 86% (90% CI 82-89%).
Darunavir is not a cure for HIV infection.
Darunavir neće izliječiti infekciju HIV-om.
Other strengths of Darunavir Mylan are available.
Dostupne su druge jačine lijeka Darunavir Mylan.
In patients taking darunavir and raltegravir (for HIV infection), rashes (generally mild or moderate) may occur more frequently than in patients taking either medicine separately.
U bolesnika koji uzimaju darunavir i raltegravir (za HIV infekciju) u kombinaciji, osipi (obično blagi ili umjereni) se mogu javiti češće nego u bolesnika koji uzimaju samo jedan od ovih lijekova.
The below list of examples of drug drug interactions is not comprehensive and therefore the label of each drug that is co-administered with darunavir should be consulted for information related to the route of metabolism, interaction pathways, potential risks, and specific actions to be taken with regards to co-administration.
Donja tablica primjera interakcija s drugim lijekovima nije sveobuhvatna, stoga je potrebno proučiti informacije o lijeku za svaki lijek koji se primjenjuje zajedno s lijekom darunavir, kako bi se informirali o metabolizmu lijeka, putovima interakcije, potencijalnim rizicima i specifičnim aktivnostima koje treba poduzeti s obzirom na istodobnu primjenu.
Pharmacokinetics of total darunavir (mean ± SD)
Farmakinetika ukupnog darunavira (srednja vrijednost ± SD)
Primary (major) PI mutations PI RAMs
Primarne (velike) IP mutacije
Emtricitabine/tenofovir alafenamide
Emtricitabin/tenofoviral afenamid
People taking darunavir may develop a skin rash.
Osobe koje uzimaju lijek darunavir mogu razviti kožni osip.
(↑ clarithromycin from CYP3A inhibition and possible P-gp inhibition)
(↑ klaritromicina zbog inhibicije CYP3A i moguće P-gp inhibicije)
ANTIEMETICS
ANTIEMETICI
Darunavir/ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.
Darunavir/ritonavir se tijekom trudnoće smije uzimati samo ako potencijalna korist opravdava potencijalni rizik.
In the rat, the combination of darunavir with ritonavir lead to a small increase in effect on RBC parameters, liver and thyroid and increased incidence of islet fibrosis in the pancreas (in male rats only) compared to treatment with darunavir alone.
Kod štakora, kombinacija darunavira s ritonavirom dovela je do malog povećanja učinka na parametre eritrocita, jetru i štitnjaču, te povećane incidencije fibroznih otočića u pankreasu (samo kod mužjaka štakora) u usporedbi s liječenjem sa samim darunavirom.
Dexamethasone (systemic)
Deksametazon (sistemski)
Since darunavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the active substance.
S obzirom da darunavir ima visoki afinitet vezanja na proteine, nije vjerojatno da bi dijaliza bila korisna pri značajnijem uklanjanju djelatne tvari.
These patients received darunavir/ritonavir 800/100 mg once daily in combination with other antiretroviral agents.
Ovi bolesnici su primili lijekove darunavir/ritonavir 800/100 mg jedanput na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
What is Darunavir Mylan?
Što je Darunavir Mylan?